Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 8/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 2/20 | 0.33 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 3/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12110391 | 0.96 | GRIN1 (0.34) | CHRM1CHRM4CHRM5GRIN1GRIN2B | |
| SCHEMBL12333177 | 0.81 | ESR2 (0.36) | CHRM1CHRM4CHRM5 | |
| SCHEMBL12110606 | 0.78 | CXCR3 (0.30) | — | |
| SCHEMBL12110555 | 0.77 | REN (0.41) | CHRM1CHRM5DRD2CHRM3 | |
| SCHEMBL12333175 | 0.77 | ESR2 (0.36) | CHRM1CHRM4CHRM5 | |
| SCHEMBL12110081 | 0.77 | CXCR3 (0.30) | — | |
| SCHEMBL14641644 | 0.74 | ATAD2 (0.41) | CHRM1GRIN1GRIN2BATAD2BRD4 | |
| SCHEMBL12107604 | 0.73 | ATAD2 (0.39) | CHRM1GRIN1GRIN2BATAD2BRD4 | |
| SCHEMBL12110302 | 0.70 | REN (0.40) | HTR1AMAOA | |
| SCHEMBL12333333 | 0.69 | ATAD2 (0.42) | CHRM1CHRM4CHRM5GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269744-A1 | Benzazepine Compound | ASTELLAS PHARMA INC. (JP) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269744-A1 | Benzazepine Compound | HTR2C, HTR3C, HTR2A | CHRM1 363/4885CHRM4 312/4885CHRM5 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.